8-K: CytoDyn Secures $30M Equity Commitment from Yorkville

CytoDyn Inc. has secured a $30 million standby equity purchase agreement with Yorkville Advisors Global, providing flexible capital for working capital and general corporate purposes.

Summary

• CytoDyn Inc. entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Yorkville) on November 3, 2025.
• The agreement provides CytoDyn with the right, but not the obligation, to sell up to $30,000,000 of its common stock to Yorkville over a 36-month period.
• Shares will be purchased at 98% of the lowest daily Volume Weighted Average Price (VWAP) during a three-consecutive-trading-day pricing period.
• CytoDyn retains sole discretion over the timing and amount of share sales, and can specify a minimum acceptable price per share.
• Proceeds are expected to be used for working capital and general corporate purposes, including debt repayment.
• As consideration, CytoDyn paid Yorkville a $25,000 structuring fee and will pay a commitment fee of 1.00% of the $30,000,000 commitment ($300,000) in common stock, issued in two tranches.
• Yorkville's beneficial ownership is capped at 4.99% of CytoDyn's then-outstanding voting power or common stock.
• The agreement requires CytoDyn to file a registration statement with the SEC for the resale of the commitment shares and shares issued through advances.

Sentiment

Score: 7

Explanation: The agreement provides a significant and flexible capital source for CytoDyn, a clinical-stage company, which is a positive development for its operational continuity and drug development. The discretionary nature and lack of warrants are favorable terms. However, the inherent dilution from equity sales and associated fees temper the overall positive sentiment.

Positives

• Secured a $30,000,000 funding commitment, providing access to capital for a clinical-stage company.
• Company maintains discretion over the timing and amount of share sales, offering financial flexibility.
• No mandatory minimum advances or non-usage fees, reducing pressure on the company.
• No warrants, derivatives, or other share classes are associated with this funding arrangement, avoiding additional dilutive instruments beyond the common stock itself.
• The funding is intended to support working capital and general corporate purposes, including debt repayment, which can strengthen the company's financial position.

Negatives

• The issuance of common stock will cause dilution to existing shareholders.
• Shares are sold at a 2% discount (98% of VWAP), which is a cost to the company.
• CytoDyn incurred a $25,000 structuring fee and a $300,000 commitment fee (paid in stock) for this facility.
• The ability to draw funds is contingent on an effective registration statement and other conditions, which could introduce delays or limitations.
• The maximum advance amount is limited to 100% of the average daily traded amount on the five preceding trading days, which could restrict the speed of capital access if trading volume is low.

Risks

• Dilution: Issuance of common shares could significantly increase the outstanding number of common shares, causing dilution to existing shareholders.
• Market Price Volatility: The actual proceeds received will depend on the frequency and prices at which the company sells its shares, which are subject to market fluctuations.
• Regulatory Compliance: Yorkville's obligation is subject to CytoDyn filing and maintaining an effective registration statement with the SEC, and compliance with other regulatory requirements.
• Operational Risks: Forward-looking statements involve risks and uncertainties related to mechanism of action, clinical trial results, product development, market position, future operating and financial performance, and business strategy.
• Black Out Periods: The company may suspend the use of the registration statement during 'Black Out Periods' (max 30 days) if necessary to amend or supplement the registration statement, during which the investor cannot sell shares under the registration statement.
• Material Outside Events: The company cannot deliver advance notices during certain 'Material Outside Events' (e.g., SEC stop orders, delisting, material misstatements), which could interrupt access to capital.

Future Outlook

The company expects to use the proceeds from this equity facility for working capital and general corporate purposes, including the repayment of debt. Management intends to utilize this commitment to further develop its program centered around leronlimab's ability to upregulate PD-L1 and views it as a flexible arrangement that allows for additional capital raises or strategic partnerships in the future.

Management Comments

• "This funding commitment from Yorkville is a solid step in the right direction for CytoDyn."
• "We will utilize this underlying commitment to further develop our program centered around the ability of leronlimab to upregulate PD-L1."
• "This type of discretionary arrangement allows us continued flexibility as we look to bring in additional capital, whether it be through additional financings or strategic partnerships."

Industry Context

For clinical-stage biotechnology companies like CytoDyn, securing non-dilutive or flexible equity financing is crucial for funding ongoing research, clinical trials, and operational expenses. Standby Equity Purchase Agreements (SEPAs) are a common financing tool in the biotech sector, offering a committed capital source that companies can draw upon as needed, providing flexibility without the immediate dilution of a large, fixed offering. This type of arrangement is particularly valuable for companies with uncertain cash flow needs or those seeking to manage dilution over time, allowing them to access funds when market conditions are favorable or specific milestones require capital.

Comparison to Industry Standards

• Flexibility: The discretionary nature of this SEPA, where CytoDyn controls the timing and amount of sales, is a standard feature designed to give companies control over dilution and market impact, similar to facilities offered by other institutional investors to small-cap biotech firms.
• Pricing: The 2% discount to VWAP is a common pricing mechanism for such facilities, reflecting the liquidity risk and commitment provided by the investor. Comparable agreements often feature discounts ranging from 1% to 5%.
• Fees: The structuring fee ($25,000) and commitment fee (1.00% of commitment, paid in stock) are typical for these types of arrangements, compensating the investor for their commitment and administrative costs.
• Ownership Limitation: The 4.99% beneficial ownership cap is standard to prevent the investor from triggering certain beneficial ownership reporting requirements (e.g., Schedule 13D) and to maintain the company's control structure.
• Use of Proceeds: Using proceeds for working capital, general corporate purposes, and debt repayment is a standard and necessary application for clinical-stage companies, aligning with industry norms for capital deployment.
• No Warrants/Derivatives: The absence of warrants or other derivatives is a positive aspect for CytoDyn, as these instruments can create additional future dilution and complexity, often seen in less favorable financing deals for companies in distress.

Stakeholder Impact

• Shareholders: Will experience dilution as new common shares are issued under the agreement. The 2% discount on share sales also impacts value. However, the funding provides capital for operations and drug development, potentially preserving long-term value.
• Creditors: Proceeds may be used for debt repayment, which could improve the company's credit profile and reduce financial risk.
• Employees: Securing funding helps ensure operational continuity, which can provide job security and support ongoing research and development efforts.
• Customers (future patients): Continued funding supports the development of leronlimab, potentially bringing new therapeutic options to patients with triple-negative breast cancer and metastatic colorectal cancer.

Next Steps

• CytoDyn will file a registration statement with the SEC to register the resale of the commitment shares and shares issued through advances.
• CytoDyn may, at its discretion, issue advance notices to Yorkville to sell common stock over the next 36 months.
• The company plans to utilize the funding to further develop its leronlimab program, specifically focusing on its ability to upregulate PD-L1.
• Management will continue to explore additional capital financings or strategic partnerships.

Key Dates

Recommendation

This financing provides a much-needed capital runway for CytoDyn, a clinical-stage company, which is a positive for its continued operations and drug development. The flexibility of the agreement and the absence of warrants are favorable terms. However, the inherent dilution from future equity sales and the company's continued reliance on external financing for its clinical programs, coupled with the early stage of its primary asset (leronlimab), suggest a "hold" recommendation. While the funding mitigates immediate liquidity concerns, the long-term success remains contingent on clinical trial outcomes and market adoption, which are highly speculative. Investors should monitor the company's progress in clinical trials and its capital deployment strategy.

Keywords

CytoDyn Inc., CYDY, Standby Equity Purchase Agreement, SEPA, Yorkville Advisors Global, Equity Financing, Capital Raise, Common Stock, Dilution, Leronlimab, Oncology, Clinical-stage, Triple-Negative Breast Cancer, Metastatic Colorectal Cancer, CCR5 receptor, Working Capital, Debt Repayment